NGNE — Neurogene Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1404644 ·
Last close
$39.64
Market Cap
$793.25M
52W High
$43.66
52W Low
$24.91
ADV30
199,523
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -33,349,000 | -30,934,000 | 263,141,000 | 124,161,000 | 25,358,000 |
| Dec 2025 | 0 | — | -27,529,000 | -24,735,000 | 288,604,000 | 103,845,000 | 23,717,000 |
| Sep 2025 | 0 | — | -23,798,000 | -20,953,000 | 287,832,000 | 71,005,000 | 22,292,000 |
| Jun 2025 | 0 | — | -26,081,000 | -22,016,000 | 297,316,000 | 58,813,000 | 24,061,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,518,000
Investing CF
$105,289,000
Financing CF
$30,619,000
CapEx
$-684,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.51
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-383,583,000
Inventory
—
Receivables
$250,000
ST Investments
$119,021,000
EBIT TTM
$-98,635,000
Pretax Income TTM
$-98,638,000
Interest Exp TTM
$3,000
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -103,328,000 | -90,351,000 | 288,604,000 | 23,717,000 | — | -77,173,000 |
| Dec 2024 | 925,000 | -82,605,000 | -75,144,000 | 335,730,000 | 25,355,000 | — | -70,603,000 |
| Dec 2023 | 0 | -55,583,000 | -36,317,000 | 222,573,000 | 36,549,000 | — | -51,422,000 |
| Dec 2022 | 0 | -56,517,000 | -55,189,000 | 109,265,000 | 255,004,000 | — | -52,824,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-34,794,000
OpCashFlow TTM
$0
Assets (Latest)
$335,730,000
Forward EPS
$-5.18
Max Pain — expiry 2027-12-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $41.55 · call volume: 27 · put volume: 322
Expected Move to 2027-12-17:
±$34.50
(83.03%) —
implied range
$7.05 –
$76.05
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STTK | Shattuck Labs, Inc. | $792.87M | $7.90 | — |
| NVCT | Nuvectis Pharma, Inc. | $779.21M | $23.87 | — |
| PHAR | Pharming Group N.V. | $811.12M | $11.46 | — |
| SLN | Silence Therapeutics plc | $826.03M | $13.29 | — |
| CYRX | Cryoport, Inc. | $827.61M | $16.34 | — |
News headlines (Yahoo Finance, 1h cache)
Neurogene Inc. Announces Pricing of $125 Million Public Offering
2026-07-01 11:00 · Yahoo
Neurogene Inc. Announces Proposed Public Offering
2026-06-30 20:01 · Yahoo
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth
2026-05-05 11:37 · Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02 20:01 · Yahoo
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
2026-06-29 11:00 · Yahoo
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
2026-08-11 11:30 · Yahoo
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
2026-06-08 11:30 · Yahoo
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference
2026-03-21 07:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.